Dean Y. Li
CIK: 0001837016
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (22 total)
- Oct 1, 2026RXRX
RECURSION PHARMACEUTICALS, INC.
Award(A)Direct3.4K shares- - Jul 1, 2026RXRX
RECURSION PHARMACEUTICALS, INC.
Award(A)Direct3.7K shares- - Jun 17, 2026RXRX
RECURSION PHARMACEUTICALS, INC.
Award(A)Direct88.4K shares- - May 5, 2026MRK
Merck & Co., Inc.
Award(A)DirectStock Option (Right to Buy)
58.2K shares- - May 5, 2026MRK
Merck & Co., Inc.
Award(A)DirectRestricted Stock Unit
19.9K shares- - Apr 29, 2026MRK
Merck & Co., Inc.
Tax Payment(F)Direct2.3K shares at avg. $110.03$256K - Apr 29, 2026MRK
Merck & Co., Inc.
Exercise(M)Direct4.7K shares at avg. $110.03$520K - Apr 1, 2026RXRX
RECURSION PHARMACEUTICALS, INC.
Award(A)Direct3.3K shares- - Feb 10, 2026MRK
Merck & Co., Inc.
Sale(S)Direct10.2K shares at avg. $117.52$1.2M - Feb 4, 2026MRK
Merck & Co., Inc.
Exercise(M)Direct15.1K shares at avg. $56.04$845K - Feb 4, 2026MRK
Merck & Co., Inc.
Sale(S)Direct15.1K shares at avg. $118.77$1.8M - Jan 26, 2026MRK
Merck & Co., Inc.
Award(A)Direct20.5K shares at avg. $107.40$2.2M - Jan 2, 2026RXRX
RECURSION PHARMACEUTICALS, INC.
Award(A)Direct2.4K shares- - Oct 1, 2025RXRX
RECURSION PHARMACEUTICALS, INC.
Award(A)Direct2K shares- - Jul 1, 2025RXRX
RECURSION PHARMACEUTICALS, INC.
Award(A)Direct1.9K shares- - Jun 18, 2025RXRX
RECURSION PHARMACEUTICALS, INC.
Award(A)Direct22K shares- - Apr 29, 2025MRK
Merck & Co., Inc.
Award(A)DirectRestricted Stock Unit
14.2K shares- - Apr 29, 2025MRK
Merck & Co., Inc.
Award(A)DirectStock Option (Right to Buy)
64.5K shares- - Apr 1, 2025RXRX
RECURSION PHARMACEUTICALS, INC.
Award(A)Direct2.3K shares- - Jan 27, 2025MRK
Merck & Co., Inc.
Award(A)Direct32.6K shares at avg. $97.94$3.2M - Jan 2, 2025RXRX
RECURSION PHARMACEUTICALS, INC.
Award(A)Direct1.6K shares- - Oct 1, 2024RXRX
RECURSION PHARMACEUTICALS, INC.
Award(A)Direct1.9K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Oct 1, 2026 |  RXRX RECURSION PHARMACEUTICALS, INC. | Award(A) | 3,378 | - | $0 | Direct |
| Jul 1, 2026 | RXRX RECURSION PHARMACEUTICALS, INC. | Award(A) | 3,747 | - | $0 | Direct |
| Jun 17, 2026 | RXRX RECURSION PHARMACEUTICALS, INC. | Award(A) | 88,424 | - | $0 | Direct |
| May 5, 2026 |  MRK Merck & Co., Inc. | Award(A) Stock Option (Right to Buy) | 58,207 | - | - | Direct |
| May 5, 2026 | MRK Merck & Co., Inc. | Award(A) Restricted Stock Unit | 19,885 | - | - | Direct |
| Apr 29, 2026 | MRK Merck & Co., Inc. | Tax Payment(F) | 2,326 | $110.03 | $255,930 | Direct |
| Apr 29, 2026 | MRK Merck & Co., Inc. | Exercise(M) | 4,722 | $110.03 | $519,562 | Direct |
| Apr 1, 2026 | RXRX RECURSION PHARMACEUTICALS, INC. | Award(A) | 3,268 | - | $0 | Direct |
| Feb 10, 2026 | MRK Merck & Co., Inc. | Sale(S) | 10,235 | $117.52 | $1,202,844 | Direct |
| Feb 4, 2026 | MRK Merck & Co., Inc. | Exercise(M) | 15,087 | $56.04 | $845,475 | Direct |
| Feb 4, 2026 | MRK Merck & Co., Inc. | Sale(S) | 15,087 | $118.77 | $1,791,824 | Direct |
| Jan 26, 2026 | MRK Merck & Co., Inc. | Award(A) | 20,469 | $107.40 | $2,198,371 | Direct |
| Jan 2, 2026 | RXRX RECURSION PHARMACEUTICALS, INC. | Award(A) | 2,381 | - | $0 | Direct |
| Oct 1, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | Award(A) | 1,961 | - | - | Direct |
| Jul 1, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | Award(A) | 1,949 | - | - | Direct |
| Jun 18, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | Award(A) | 22,016 | - | - | Direct |
| Apr 29, 2025 | MRK Merck & Co., Inc. | Award(A) Restricted Stock Unit | 14,166 | - | - | Direct |
| Apr 29, 2025 | MRK Merck & Co., Inc. | Award(A) Stock Option (Right to Buy) | 64,481 | - | - | Direct |
| Apr 1, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | Award(A) | 2,268 | - | - | Direct |
| Jan 27, 2025 | MRK Merck & Co., Inc. | Award(A) | 32,621 | $97.94 | $3,194,901 | Direct |
| Jan 2, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | Award(A) | 1,647 | - | $0 | Direct |
| Oct 1, 2024 | RXRX RECURSION PHARMACEUTICALS, INC. | Award(A) | 1,925 | - | $0 | Direct |
1-22 of 22 transactions
About Li Dean Y
Li Dean Y (SEC CIK 0001837016) files insider reports with the SEC as Director of RECURSION PHARMACEUTICALS, INC. (RXRX) and Executive VP & President, MRL of Merck & Co., Inc. (MRK).
Signal8 holds 18 ownership filings by Li Dean Y, all Form 4s, filed between Oct 4, 2024 and Oct 2, 2026. Those filings report 22 transactions, from Oct 1, 2024 to Oct 1, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Li Dean Y's filings is in SALT LAKE CITY, UT.
Recent filings by Li Dean Y
- Oct 1, 2026: Grant or award of RXRX shares (Form 4, code A).
- Jul 1, 2026: Grant or award of RXRX shares (Form 4, code A).
- Jun 17, 2026: Grant or award of RXRX shares (Form 4, code A).
- May 5, 2026: Grants or awards of MRK derivative securities (2 lines, Form 4, code A).
- Apr 29, 2026: Tax withholding of MRK shares (Form 4, code F).
Other insiders filing for RECURSION PHARMACEUTICALS, INC. (RXRX)
- Borgeson Blake, Director
- HERSHBERG ROBERT, Director
- Dar Zavain, Director
- Taylor Ben R, Chief Financial Officer
- Khan Najat, CEO and President
- Hallett David, Chief Scientific Officer